Printer Friendly

Lipophilic stinging nettle extracts possess potent anti-inflammatory activity, are not cytotoxic and may be superior to traditional tinctures for treating inflammatory disorders.


Keywords: Urtica dioica (stinging nettle) Accelerated solvent extraction (ASE) Anti-inflammatory Rheumatoid arthritis Osteoarthritis Nuclear factor-kB


Extracts of four plant portions (roots, stems, leaves and flowers) of Urtica dioica (the stinging nettle) were prepared using accelerated solvent extraction (ASE) involving water, hexanes, methanol and dichloromethane. The extracts were evaluated for their anti-inflammatory and cytotoxic activities in an NF-KB luciferase and MIT assay using macrophage immune (RAW264.7) cells. A standardized commercial ethanol extract of nettle leaves was also evaluated. The methanolic extract of the flowering portions displayed significant anti-inflammatory activity on par with a standard compound celastrol (1) but were moderately cytotoxic. Alternatively, the polar extracts (water, methanol, ethanol) of the roots, stems and leaves displayed moderate to weak anti-inflammatory activity, while the methanol and especially the water soluble extracts exhibited noticeable cytotoxicity. In contrast, the lipophilic dichloromethane extracts of the roots, stems and leaves exhibited potent anti-inflammatory effects greater than or equal to 1 with minimal cytotoxicity to RAW264.7 cells. Collectively these results suggest that using lipophilic extracts of stinging nettle may be more effective than traditional tinctures (water, methanol, ethanol) in clinical evaluations for the treatment of inflammatory disorders especially arthritis. A chemical investigation into the lipophilic extracts of stinging nettle to identify the bioactive compound(s) responsible for their observed anti-inflammatory activity is further warranted.

Published by Elsevier GmbH.


Herbal medicines have the potential to provide efficacious treatments for inflammatory disorders, particularly rheumatoid arthritis (RA) or osteoarthritis (OA) (Khanna et al. 2007; Soeken et al. 2003; Long et al. 2001). Historically, dozens of plants species have been repeatedly and independently selected by multiple cultures around the world for their analgesic/anti-inflammatory effects (Venkatesha et al. 2011a). Selected examples include Tripterygium wilfordii (thunder God vine), Camellia sinensis (green tea), Uncaria tomentosa (cat's claw), and Zingiber officinale (ginger). Extracts of these plants and or their characterized bioactive com-pound(s) demonstrate potent anti-inflammatory activity in vitro by inhibiting targets in the nuclear factor kappa B (NF-kB) pathway (Venkatesha et al. 2011a: Khanna et al. 2007: Ahmed et al. 2005). Furthermore evaluations of each of these herbal medicines have shown positive anti-arthritic effects in vivo as well as clinically against RA or OA (Ahmed et al. 2005).

Another lesser known cosmopolitan ethnobotanical medicine is Urtica dioica (the stinging nettle) used throughout North America and Europe for treating inflammatory disorders such as OA (Setty and Sigal 2005). Several preclinical studies demonstrating the anti-inflammatory therapeutic potential and proposed mechanism of action (MOA) of nettle have been reported (Chrubasik et al. 2007a), most notably its inhibition of myeloid dendritic cells (Broer and Behnke 2002) as well as targets in the NF-kB pathway (Riehemann et al. 1999), however its precise MOA is not clear. Ten clinical trials evaluating its use for the treatment of OA have been conducted and generated mixed results in terms of their efficacy (Rayburn et al. 2009; Jacquet et al. 2009; Chrubasik et al. 2007a). The root extracts of nettle have also been studied clinically for treatment of benign prostatic hyperplasia (BPH) (Chrubasik et al. 2007b). Also noteworthy is that the bioactive com-pound(s) responsible for these reported activities remains poorly understood.

A number of structural classes have been reported from extracts of nettle and selected examples are shown in Fig. 1 (Cummings and Olsen 2011; Chrubasik et at. 2007a; Ji et al. 2007).

Surprisingly, definitive reports using bioassay guided fractionation to link any potent anti-inflammatory compound(s) derived from nettle for treating OA are lacking (Schulze-Tanzil et al. 2002). In addition several different extract preparations (e.g. water, ethanol, and propanol) have exhibited success clinically, making it difficult to pinpoint the overall active chemistry and further compare the efficacy of clinical studies side-by-side (Cameron et at. 2009; Randall et al. 2008; Chrubasik et al. 2007a). Traditionally water and ethanol soluble extracts of nettle have been used to investigate its anti-inflammatory effects. Unfortunately, standardized extracts of the more polar constituents have failed to agree with clinical efficacy (Chrubasik et al. 2007a). Interestingly, few investigators have looked closely into the lipophilic extracts of U. dioica despite previous reports of anti-inflammatory activity with potentially undefined chemistry (Chrubasik and Eisenberg 1999).

In a previous pilot clinical trial, we demonstrated that the topical use of a proprietary ethanol based extract of nettle for treatment of OA was both well tolerated and likely effective in reducing pain and improving function (Rayburn et al. 2009). Before initiating further OA evaluations, we realized that the MOA (Setty and Sigal 2005) and most effective formulation(s) of nettle (Chrubasik et al. 2007a) were not clearly defined for treating OA and that we could possibly benefit from conducting our own pre-clinical investigations to address these concerns. The purpose of the present study was to start by identifying the most potent extracts and ultimately the bioactive compound(s) derived from stinging nettle to facilitate evaluation of their anti-inflammatory and antiarthritic mechanisms in order to lead to optimal formulations that would be the most effective for OA clinical evaluations. Based on the anti-inflammatory results reported for T. wilfordii, C. sinensis, U. tomentosa, and Z. officinale using models involving NF-KB (Ahmed et al. 2005), the fact that the NF-KB pathway has emerged as a potential anti-arthritic therapeutic target (Venkatesha et at. 2011a; Khanna et al. 2007), and the positive results observed for these species in treating RA and OA clinically (Ahmed et al. 2005), it seemed logical to begin our investigation of nettle in two parts. First by collecting fresh specimens of U. dioica and separating them into four major portions (roots, stems, leaves and flowers) for high-throughput accelerated solvent extraction (ASE) (Johnson et al. 2010) and second by evaluating these extracts for their anti-inflammatory and cytotoxic activities using a previously reported NF-KB luciferase and MIT assay (Johnson et at. 2012).

Materials and methods

Motivated by the positive results from our pilot clinical trial we began by obtaining wild stinging nettle specimens (-1 kg) of U. dioica from the Monterey Bay region of California (where the Mutsun Native American tribe has used the plant medicinally for centuries) and conducted an in vitro anti-inflammatory analysis of extracts from the roots (12.0 g), sterns (11.2g), leaves (15.6g) and flowers (7.9g). We employed our nuclear factor kappa B (NF-kB) luciferase assay (Johnson et al. 2012) to measure the reduction of inflammation of transfected macrophage immune (RAW264.7) cells that were stimulated by the endotoxin lipopolysaccharide (LPS). Cytotoxicity of these samples was also measured against macrophage (RAW264.7) immune cells using our MTF assay (Johnson et al. 2012). Extracts were prepared using our high-throughput extraction protocol involving ASE (Johnson et al. 2010) and included water ([H.sub.2]0), methanol (Me0H), dichloromethane (DCM) and hexanes. We further compared the nettle extracts with a commercial ethanol leaf extract, obtained from Gaia Herbs Inc., versus the standard anti-inflammatory agent celastrol (1) and the cytotoxin doxorubicin.

NF-kB luciferase assay

Extracts were tested in an NF-KB luciferase reporter assay in mouse macrophage (RAW264.7) immune cells to determine NF-KB activity. Stably transfected RAW264.7 cells with the NF-KB reporter gene were plated and evaluated. Following a 24h recovery period, the cells were treated with the extract(s) for an additional 18h in the presence of LPS (100 ng/m1). To check NF-kB-luciferase activity, the Luciferase Reporter Assay System purchased from Promega (Madison, WI) were used. Cell lysates (15 [micro],1) from treated RAW264.7 cells were placed in opaque 96 well plates. Luciferase Assay Reagent (50 [micro]l) was injected and read by a fluorometer (LMAX 2, Molecular devices). All extracts were evaluated in triplicate (n = 3) for their effects on RAW264.7 cells. The standard anti-inflammatory agent celastrol was obtained from Cayman Chemical Company, Ann Arbor, MI, USA.

MTT cytotoxicity assay

Extracts were tested at 10 [micro]g/ml using the mrr assay in murine macrophage (RAW264.7) immune cells. Cells in 96-well plates in the required growth medium were treated with extracts dissolved in DMSO for 20 h (RAW264.7). After incubation, MTT solution was added to wells and incubated for another 2 h. Media were removed and DMSO was added to dissolve purple precipitates. Then plates were read at 570 nm using a plate reader. All extracts were evaluated in triplicate (n = 3) for their effects on RAW264.7 cells. The standard cytotoxic agent doxorubicin was obtained from Cayman Chemical Company, Ann Arbor, MI, USA.


The anti-inflammatory and cytotoxic activities of four extracts from four plant portions of U. dioica evaluated in the NF-kB luciferase assay (top) and MIT cytotoxicity assay (bottom) are shown in Fig. 2. These samples were screened alongside the standard compounds celastrol (1, 250 nM) and the known cytotoxin doxorubicin (10 [micro]M). The yields of the water ([H.sub.2]0) extracts (in parenthesis) evaluated from the roots (192.7 mg), stems (248.1 mg), leaves (320.1 mg) and flowers (234.3 mg) displayed no anti-inflammatory effects up to 10 [micro]g/m1 in the NF-kB luciferase assay. In contrast, the stems and leaves [H.sub.2]0 extracts were noticeably cytotoxic to macrophage (RAW264.7) immune cells in the MIT assay (asterisks), but were less toxic then doxorubicin. The methanol (Me0H) extracts of the roots (256.1 mg), stems (1042.2 mg) and leaves (674.4 mg) were considerably less active than 1 in terms of their ability to reduce LPS induced activation of NF-kB and were on par with a standardized commercial ethanol leaf extract (40 [micro]g/m1), and most were slightly cytotoxic. The Me0H extract (333.1 mg) of the flowering portion of U. dioica, effectively reduced LPS induced inflammation in the NF-kB assay but was also moderately cytotoxic in the MIT assay. Interestingly, the dichloromethane (DCM) extracts (boxed) of the roots (12.7 mg), stems (41.5 mg) and leaves (190.3 mg) were greater than or equal to I at reducing LPS induced inflammation in the NF-kB assay at 10 [micro]g/ml. While yields of the hexane extracts of the roots (1.0 mg), stems (2.9 mg), leaves (13.3 mg) and flowers (20.7 mg) also displayed anti-inflammatory activity they were not as potent as the DCM extracts. Most importantly all of the lipophilic extracts exhibited minimal cytotoxicity to RAW264.7 cells in the MIT assay and were comparable to 1.


An important aspect of this study involved using the NF-kB luciferase assay alongside the MIT cytotoxicity assay to identify selective non cytotoxic anti-inflammatory extracts. Many extracts or compounds can demonstrate potent anti-inflammatory effects by inhibiting LPS stimulated NF-kB activation but do so through a cytotoxic mechanism (e.g. doxorubicin, see Fig. 2), which serves to diminish their therapeutic potential. To the best of our knowledge, this is the first report to screen nettle extracts for both their anti-inflammatory and cytotoxic activities in macrophage (RAW264.7) immune cells side by side. This heightens the impact of our discovery as the above results indicate the potential for in vivo and or clinical anti-inflammatory activity, without significant toxicity using lipophilic extracts, thereby improving the therapeutic index when administering nettle.

A recent clinical study showed that an unspecified dried extract of nettle combined with fish oil, vitamin E and zinc, in a proprietary product ([Phytalgic.sup.[R]]), decreased disease scores in patients with OA and reduces the use of analgesics or non steroidal anti-inflammatory drugs (Jacquet et al. 2009). The results of this study showed great promise, although some concerns were raised regarding detection bias and the way in which the overall study was conducted (Christensen and Bliddal 2010). Regardless, if larger independent studies can repeat the incredible observed effect size of ~0.5 reported by Jacquet et al. (2009), OA therapy may be in for a dramatic change. Of considerable interest is that the nettle extract and fish oil used in this product were the only substances in which the chemistry was undefined in terms of its ascribed anti-arthritic activity. This leaves the reader to ponder whether the unreported compounds in nettle play a most crucial role in treating OA.

Some of the most encouraging results obtained overall from herbal medicines for the treatment of arthritis are from using T. wilfordii (Tao et al. 2002) which has spawned widespread investigation into the therapeutic potential of the extracts and or compounds prepared from this species. For example, a U.S. NilL-sponsored Phase 2b clinical trial using extracts of T. wilfordii for the treatment of RA showed significant improvement measured in the group receiving the plant extract (Goldman-Mansky et al. 2009). Therapeutic lead compounds from T. wilfordii with proven anti-inflammatory activity that inhibit the NF-KB pathway include the lipophilic triterpene celastrol (1) and diterpenoid epoxide trip-tolide (2) (Fig. 3) (Lee et al. 2006; Ma et al. 2007). Compound 1 is currently being pursued as an important anti-arthritic therapeutic lead based on impressive results of both 1 and its parent extract demonstrating potent in vivo activity in the rat adjuvant-induced arthritis model of human RA (Venkatesha et al. 2011b). Compound 2 or its derivatives are in Phase I clinical trials for treating RA (Zhou et al. 2012). The fact that lipophilic extracts of nettle are on par with the anti-inflammatory standard 1 in our NF-KB and MTT assays in terms of their selective potency is promising and suggests that further exploration into the bioactive compound(s) within these extracts could uncover new therapeutic leads for treating OA.


Several noteworthy conclusions can be drawn from our investigation of the extracts of U.dioica (the stinging nettle). First, the polar water ([H.sub.2]0) extracts evaluated demonstrated no ability to reduce inflammation stimulated by LPS in our NF-kB luciferase assay. In fact [H.sub.2]0 extracts of the stems and leaves demonstrated noticeable cytotoxicity in the MIT assay. Second, most of the polar Me0H extracts of our specimens (including the roots, stems and leaves) were far less effective than the standard anti-inflammatory agent celastrol (1) and were comparable to a commercial ethanol extract of stinging nettle in terms of their activity. Third, in accordance with reports by others (Chrubasik et al. 2007a,b), the Me0H extract of the flowering portion of nettle displayed significant anti-inflammatory activity however moderate cytotoxicity was also observed. Lastly and of particular note, the lipophilic DCM extracts of the roots, stems and leaves were equivalent to or more potent than the standard 1 at reducing LPS induced inflammation in the NF-KB luciferase assay and were the least cytotoxic.

Further preclinical work is needed to elucidate the structure(s) of the active component(s) in the bioactive extract portions of nettle, and to determine optimal dosage and route of delivery. Subsequently, clinical trials can define a role for stinging nettle in the treatment of patients with OA and other inflammatory disorders. In summary, these findings suggest that using lipophilic extracts of the roots, stems or leaves of stinging nettle may serve as complimentary and or more effective formulations than traditional tinctures to undergo in vivo and or clinical evaluations for treating diseases involving inflammation, including OA. Ultimately ongoing investigations into the chemistry responsible for the anti-inflammatory activity observed in lipophilic nettle extracts merits further consideration.


This work was supported by grants from the NIH Fogarty International Center, International Cooperative Biodiversity Groups, award number 1U01TWO08160-01 and Agricultural Food Research Initiative of the National Institute of Food and Agriculture, USDA, Grant #35621-04750. We are grateful to Professor Philip Crews (UC Santa Cruz) for allowing us to use his laboratory to conduct this research.


Ahmed, S., Antintiyo, J.. Malemud, C.J., Haqqi, T.M., 2005. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis. Evidence-Based Complementary and Alternative Medicine 2, 301-308.

Broer, J., Behnke, B., 2002. Immunosuppressant effect of IDS 30, a stinging nettle leaf extract, on myeloid dendritic cells in vitro. Journal of Rheumatology 29, 659-666.

Cameron, M.. Gagnier, J.J., Little, C.V., Parsons, T.J.. Blumle, A., Chrubasik, S.A., 2009. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 1. Phytotherapy Research 23, 1497-1515.

Christensen, R., Blicldal, H., 2010.1s [Phytalgic.sup.[R]] a golcl mi ne for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment. Arthritis Research and Therapy 12, R105.

Chrubasik, S.A., Eisenberg, E., 1999. Treatment of rheumatic pain with kampo medicine in Europe. Part II. Urtica dioica. Pain Clinic 11, 179-185.

Chrubasik, J.E., Roufogal is, B.D., Wagner, H., Chrubasik, S.A., 2007a. A comprehensive review on nettle effect and efficacy profiles. Part I: Herba urticae. Phytomedicine 14,423-435.

Chrubasik, J.E., Roufogalis, B.D., Wagner, H., Chrubasik, S.A., 200711 A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: Urticae radix. Phytomedicine 14, 568-579.

Cummings, A.J., Olsen, M., 2011. Mechanism of action of stinging nettles. Wilderness and Environmental Medicine 22, 136-139.

Goldman-Mansky, R., Wilson, M., Fleischmann, R., Olsen, N.. Silverfield, J., Kempf, P.. Kivitz, A., Sherrer, Y., Pucino, F., Csako, G., Costello, R., Pham, T.H., Synder, C., Fleijcle, D., Tao, X., Wesley, R., Lipsky, P.E., 2009. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 51, 229-240.

Jacquet, A., Girodet, P., Pariente, A., Forest, K., Mallet, L, Moore, N., 2009. Phytalgie, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomized double-blind placebo-controlled clinical trial. Arthritis Research and Therapy 11, R192.

Ji. T., Liu, C., Wang, A., Yang, J., Su, Y., Yuan, L, Feng, X., 2007. Chemical constituents of Urtica dioica L. grown in Tibet autonomous region. Zhong yao cai =Journal of Chinese Medicinal Materials 30, 662-664.

Johnson, T.A., Morgan, M.V.C., Aratow, N.A., Estee, S.A., Sashidhara, K.V., Loveridge, S.T., Segraves, N.L, Crews, P., 2010. Assessing pressurized liquid extraction for the high-throughput extraction of marine-sponge-derived natural products. Journal of Natural Products 3, 359-364.

Johnson, T.A., Sohn, J., Vaske, Y.M., White, K.N., Cohen, T.L, Vervoort. H.C., Tenney, K., Valeriote, F.A., Bjeldanes, LF., Crews, P., 2012. Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/E1SD libraries. Bioorganic and Medicinal Chemistry 20, 4348-4355.

Khanna, D., Sethi, G., Ahn, K.S., Pandey, M.K., Kunnamakkara, A.B., Sung, B., Aggarwal, A., Aggarwal, B.B., 2007. Natural products as a gold mine for arthritis treatment. Current Opinion in Pharmacology 7,344-351.

Lee, J., Koo, T.H.. Yoon, H., Jung, H.S., Jin. H.Z., Lee, K., Hong, Y., Lee, J.J., 2006. Inhibition of NF-KB activation through targeting1KB kinase by celastrol, a quinone methide triterpenoid. Biochemical Pharmacology 72, 1311-1321.

Long, L. Soeken, K., Ernst, E., 2001. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology 40, 779-793.

Ma, J., Dey, M., Yang, H., Poulev, A., Pouleva, R., Dorn, R., Lipsky, R.E., Kennelly, E.J., Raskin, 1., 2007. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry 68, 1172-1178.

Randall, C., Dickens, A., White, A., Sanders, H., Fox, M., Cambell, J., 2008. Nettle sting for chronic knee pain: a randomized controlled pilot study. Complementary Therapies in Medicine 16,66-72.

Rayburn, K., Fleischbein, E., Song, J., Allen, B., Kundert, M., Leiter, C., Bush, T., 2009. Stinging nettle cream for osteoarthritis. Alternative Therapies in Health and Medicine 15 (4). 60-61.

Riehemann, K., Behnke, B., Schulze-Osthoff, K., 1999. Plant extracts from stinging nettle (Urtica dioica), an anti-rheumatic remedy, inhibit the proinflammatory transcription factor NF-KB. FEBS Letters 442. 89-94.

Schulze-Tanzil, G., De Souza, P., Behnke, B., Klingelhoefer, S., Scheid, A., Shakibaei, M., 2002. Effects of the antirheumatic remedy Hox alpha - a new stinging nettle leaf extract - on matrix metalloproteinases in human chondrocytes in vitro. Histology and Histopathology 17, 477-485.

Setty, A.R., Sigal, LH., 2005. Herbal medications: commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Seminars in Arthritis and Rheumatism 34, 773-784.

Soeken, K.L., Miller, S.A., Ernst, E., 2003. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology 42, 652659.

Tao, X., Younger, J., Fan, F.Z., Wang, B., Lipsky, P.E.. 2002. Benefit of an extract of Tripterygium wilfordii hook F in patients with rheumatoid arthritis. Arthritis and Rheumatism 7, 1735-1743.

Venkatesha, Berman. B.M., Moudgil, K.D., 201 I a. Herbal medicinal products tar-get defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorganic and Medicinal Chemistry 19,21-29.

Venkatesha, S.H., Yu, H., Rajaiah, R., Tong, L. Moudgi I, K.D., 2011b. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. Journal of Biological Chemistry 17. 15138-15146.

Zhou, Z., Yang, Y., Ding, J., Li, Y., Miao, Z., 2012. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Natural Products Reports 29, 457-475.

* Corresponding author at: Department of Chemistry & Biochemistry, University of California, Santa Cruz, CA 95064, United States. Tel.: +1 831 459 4280.

** Corresponding author. Tel.: +1 408 852 2200.

E-mail addresses:, (T.A. Johnson), (K. Rayburn).

0944-7113/$ - see front matter. Published by Elsevier GmbH.

Tyler A. Johnson (a), (b), *, Johann Sohn (a), Wayne D. Inman (b), Leonard F. Bjeldanes (a), Keith Rayburn (c), **

(a.) Department of Nutritional Sciences & Toxicology, University of California, Berkeley, CA 94720, United States

(b.) Department of Chemistry & Biochemistry, University of California, Santa Cruz, CA 95064, United States

(c.) Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, United States
COPYRIGHT 2013 Urban & Fischer Verlag
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Johnsona, Tyler A.; Sohna, Johann; Inman, Wayne D.; Bjeldanesa, Leonard F.; Rayburn, Keith
Publication:Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
Article Type:Report
Geographic Code:1USA
Date:Jan 15, 2013
Previous Article:[beta]-Asarone, an active principle of Acorus calamus rhizome, inhibits morphogenesis, biofilm formation and ergosterol biosynthesis in Candida...
Next Article:Can the Pelargonium sidoides root extract EPs[R] 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children?

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters